Blincyto® (blinatumomab) – Expanded indication
July 11, 2017 – Amgen announced the FDA approval of Blincyto (blinatumomab) injection, for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.
Download PDF
